Prospective, Single center, Registry to Evaluate the Long-term Clinical Safety and Efficacy of the Resolute Integrity drug eluting stent in an all-comers population.
- Conditions
- Coronary artery disease (CAD)
- Registration Number
- JPRN-UMIN000009909
- Lead Sponsor
- Department of Cardiovascular Internal Medicine, Kuki General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Not provided
1.Patients with cardiogenic shock 2.Patients who are pregnant or possibly pregnant 3.Patients who cannot comply with the antiplatelet therapy specified for this clinical study 4.Patients scheduled to undergo elective surgery within 6 months post-index PCI 5.Patients with a history of allergic reaction or hypersensitivity to zotarolimus, sirolimus, tacrolimus, everolimus, or other analogues or derivatives 6.Patients with an allergic reaction to antiplatelet or anticoagulant drugs, such as heparin, aspirin, ticlopidine, or clopidogrel, or contrast agents, or those who cannot tolerate these substances and to whom appropriate treatments cannot be given 7. Patient who underwent stent treatment with BMS in other lesions within 6 months prior to the conduct of index PCI of the target vessel
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method